The company
Lycia Therapeutics, Inc.
LYCA · Nasdaq
We hold no 150-day reading for LYCA yet: it needs about 200 sessions of history. Biotechnology: 17% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 27% (−6 points in four weeks).
Statistics
- Rotation
- not in the set
- Weeks in an uptrend
- —
- Industry in uptrend
- 17% -9 in 4 wk
- Insider buys, 12 months
- $37.7M
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 0
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 0 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 8,729at $25.84 | 27 Oct 2026filed 27 Oct 2026 |
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 31,067at $26.84 | 27 Oct 2026filed 27 Oct 2026 |
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 1,944,444at $18.00 | 26 Oct 2026filed 27 Oct 2026 |
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 8,261at $26.97 | 26 Oct 2026filed 27 Oct 2026 |
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 24,560at $25.68 | 23 Oct 2026filed 27 Oct 2026 |
| Venrock Healthcare Capital Partners Iii, L.p.10% owner | bought | 28,379at $26.11 | 23 Oct 2026filed 27 Oct 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|
Everyone who traded it
Same industry
No other stock in its industry this week.
Government contracts
No federal award is tied to it.
From its SEC filings
No ratio computed from its SEC filings yet.
Analyst forecasts
No analyst forecasts yet.